A Phase 2 Study To Evaluate The Safety, Tolerability And Efficacy Of Levofloxacin Inhalation Solution (MP-376) Administered For 5 Days Every 28 Days To Prevent Acute Exacerbations In High Risk COPD Patients | Publicación